The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.

Analysis of the Mobility domain demonstrates a slight trend towards improvement over time, with 76.3% of PwHA reporting ‘no problems’ or ‘slight problems’ at Week 73 (n = 90/118) compared with 70.6% at baseline (n = 120/170). 3.5 Work absences With emicizumab, fewer employed participants missed workdays than in the 28 days prior to study enrolment (Figure 5 ).

also in 4,078 other papers